Online inquiry

IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5716MR)

This product GTTS-WQ5716MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&CEACAM5 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4; NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 1048
UniProt ID P07766; P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5716MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8095MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ4412MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ1732MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ1110MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ3601MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ2716MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG103
GTTS-WQ1718MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ3311MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ASN-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW